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(57) ABSTRACT 
A device for collecting exhaled breath condensate from a 
subject. The device comprises a plunger assembly and a stop-
per. The stopper is connected to the plunger disk of the 
plunger assembly by a plurality of support pins and is con-
figured for sealing engagement. The device is utilized to 
collect exhaled breath condensate from both spontaneously 
breathing and mechanically ventilated subjects and the 
devices utilized to determine whether lipopolysaccharide is 
present in the collected exhaled breath condensate. 
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UTILIZING LIPOPOLYSACCHARIDE IN 
EXHALED BREATH CONDENSATE TO 
DIAGNOSE GRAM NEGATIVE PNEUMONIA 
CROSS-REFERENCES TO RELATED 
APPLICATION 
[0001] This application is a continuation-in-part of and thus 
is entitled to the benefit of, and claims priority to U.S. Divi-
sional patent application Ser. No. 12/157,133 filed Jun. 6, 
2008, which claims the benefit ofU.S. patent application Ser. 
No. 11/135,265 filed May 23, 2005, now U.S. Pat. No. 7,828, 
741, which claims the benefit of provisional U.S. Patent 
Application Ser. No. 60/577,641, filed Jun. 7, 2004. U.S. 
patent application Ser. No. 11/135,265 is also a continuation-
in-part of U.S. patent application Ser. No. 10/742,721 filed 
Dec. 19, 2003, which claims the benefit of provisional U.S. 
Patent Application Ser. No. 60/434,916 filed Dec. 20, 2002 
and provisional U.S. Patent Application Ser. No. 60/447,581 
filed Feb. 14, 2003. In addition, U.S. patent application Ser. 
No. 10/742,721 is a continuation-in-part of U.S. patent appli-
cation Ser. No. 10/778,477 filed Feb. 13, 2004, now U.S. Pat. 
No. 7,547,285, which claims the benefit of provisional U.S. 
Patent Application Ser. No. 60/447,581 filed Feb. 14, 2003. 
The entirety of each of the aforementioned applications is 
incorporated herein by reference. 
FIELD OF THE INVENTION 
[0002] The present invention relates generally to a method 
and devices for diagnosing gram negative bacterial pneumo-
nia and, in particular, to an improved device for collecting 
exhaled breath condensate. The exhaled breath condensate is 
used in a method of diagnosing gram negative bacterial pneu-
monia by detecting the presence of lipopolysaccharide in 
exhaled breath condensate collected via the improved collec-
tion device. 
BACKGROUND OF THE INVENTION 
[0003] Pneumonia represents a common disease with sig-
nificant morbidity and mortality. Pneumonia is the number 
one cause of death by infectious disease and the sixth most 
common cause of death in the United States. The National 
Hospital Ambulatory Medical Care Survey found that in 
2001, 1.48 million emergency department visits were related 
to a diagnosis of pneumonia. The National Hospital Dis-
charge Survey found that in 1998, 1.32 million patients were 
discharged after having been treated for pneumonia. 
[0004] Pneumonia can be caused by lung infection of many 
types of microorganisms, including viruses, chlamydia, 
mycoplasma, protozoa, fungi, and bacteria. For a patient with 
suspected pneumonia, the clinician has a duty to determine 
the exact cause of infection because the identity of the infec-
tious agent dictates the choice of antimicrobial treatment. The 
most common cause in Western society is bacterial pneumo-
nia, and when bacterial pneumonia is suspected, clinicians 
generally seek to categorize the cause of bacterial pneumonia 
as Gram positive, Gram negative or anaerobic. 
[0005] In particular, clinicians are motivated to identify the 
presence of Gram negative bacterial infection because Gram 
negative lung infections are aggressive and are associated 
with higher rates of complications and death. The Gram nega-
tive feature of bacteria refers to the color of the bacteria after 
a staining protocol that will be well understood by those 
skilled in the art. Gram negative bacterial infections, includ-
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ing gram negative bacterial pneumonia, require specific anti-
microbial therapy, which is different from treatment for other 
types of bacterial infections, and warrant an elevated level of 
financial reimbursement from third party payors such as 
Medicare. 
[0006] In current clinical practice, pneumonia is diagnosed 
by combining clinical, laboratory and radiographic informa-
tion. In general, features such as the patient's complaint, the 
patient's vital signs, the peripheral white blood count, and the 
results of chest radiography are used to determine the pres-
ence or absence of pneumonia. When these sources of data fit 
a typical pattern, the diagnosis can be made with reasonable 
clinical certainty, and antimicrobial therapy can be initiated 
prior to the results of bacteriological cultures. Although non-
specific clinical data is often used to initiate antibiotic treat-
ment for Gram negative infection, common practice dictates 
that the final diagnosis of Gram negative pneumonia requires 
more specific evidence of Gram negative bacterial lung infec-
tion. 
[0007] Toward this goal, a Gram's stain can be performed 
immediately on sputum that is coughed from the lower air-
ways, and microscopic analysis may reveal bacteria with 
morphology and color suggesting Gram negative infection. 
However, useful sputum samples are notoriously difficult to 
obtain from humans with pneumonia. When blood specimen 
cultures from a patient who has a clinical pattern consistent 
with pneumonia grow a Gram negative bacterium, this pro-
vides a specific indication of Gram negative pneumonia. 
Unfortunately, more often than not, the blood is sterile in a 
patient with Gram negative pneumonia. 
[0008] In addition, a patient's blood may be examined for 
endotoxin concentration using chemical assays for the endot-
oxin molecule. However, endotoxin concentrations have been 
found to be an inaccurate predictor of either the cause or 
severity of the more general sepsis syndrome. Endotoxin 
concentrations in the blood may fluctuate widely over short 
time periods. Further, certain disease states, including liver 
disease, polytrauma, hypertension, and hematological malig-
nancies are associated with chronically elevated endotoxin 
concentrations in the absence of clinically significant infec-
tion. No study has examined whether circulating endotoxin 
concentrations can predict a gram negative source of pneu-
moma. 
[0009] A sensitive and specific method to diagnose Gram 
negative lung infection is to perform bronchalveolar lavage 
and to perform a bacteriological culture on the lavage fluid. 
Another method is to chemically assay for lipopolysaccha-
ride content in bronchoalveolar lavage samples. Investigators 
using this method found that high concentrations of 
lipopolysaccharide are associated with concomitant growth 
of gram negative bacteria in cultures of the bronchalveolar 
fluid. A complete description of this method may be found in 
Flanagan, P. G., Jackson, S. K., Findlay, G., "Diagnosis of 
Gram negative, ventilator associated pneumonia by assaying 
endotoxin in bronchial lavage fluid", J. Clin. Pathol. 2001, 
54:107-110 and Pugin, J., Auckenthaler, R. and Delaspre, 0., 
"Rapid Diagnosis of gram-negative pneumonia by assay of 
endotoxin in bronchoalveolar lavage fluid", Thorax 1992, 
47:547-549. Both methods have the drawbacks that special 
endoscopic equipment and subspecialty expertise are 
required and that they are relatively invasive and uncomfort-
able procedures. Moreover, known culture methods require at 
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least 24 hours to obtain results. As such, a patient may wait for 
up to at least 24 hours before receiving an effective antibiotic 
treatment. 
[0010] The cell wall of Gram negative bacteria comprises 
endotoxins. Endotoxins are toxic materials released by bac-
terium on bacterial lysis. While endotoxins were first recog-
nized for their ability to induce fever, they are now known to 
have a broad spectrum ofbiologic activities. On bacteriolysis, 
endotoxins consisting of aggregates of lipopolysaccharides 
and protein and lipids, are released from the bacterium into 
surrounding medium. Endotoxins consist primarily of 
lipopolysaccharide ("LPS") with various amounts of protein 
and lipid. Since almost all of the biologic activities usually 
attributable to bacterial endotoxins can also be elicited with 
isolated chemically pure lipopolysaccharide, the terms 
"endotoxin" and "lipopolysaccharide" are used interchange-
ably. 
[0011] From a pathogenic standpoint, the presence of 
lipopolysaccharide is one of the most important implications 
of a Gram negative infection. As such, detecting lipopolysac-
charide in a patient's bodily fluid is an indicator of Gram 
negative bacterial infection. More specifically, the presence 
oflipopolysaccharide in a patient's bodily fluid is an impor-
tant potential indicator of Gram negative pneumonia. 
[0012] The present invention overcomes the above-de-
scribed clinical disadvantages of diagnosing Gram negative 
bacterial pneumonia by performing an assay for lipopolysac-
charide on the liquid derived from condensation of exhaled 
breath. Using novel devices and methods described herein, 
exhaled breath condensate may be obtained from a spontane-
ously breathing subject via a mouthpiece, facemask or other 
similar means or from a subject breathing with the assistance 
of a mechanical ventilator via a connection to the expiratory 
tubing of the mechanical ventilator. An additional advantage 
of the present invention is the shorter time period for diag-
nosing a Gram negative bacterial infection, such as pneumo-
nia, than is required for other diagnostic methods. 
[0013] Alternative devices for collecting exhaled breath 
condensate are also known. These devices include those dis-
closed in Gaston et al., U.S. Pat. Nos. 6,033,368 and 6,419, 
634; Hunt et al., U.S. Pat. No. 6,585,661; Baddour, U.S. 
application Ser. No. 10/257,912; and EU Patent No. 0,759, 
169 Bl to Winsel et al., all of which are incorporated by 
reference herein in their entireties. In addition, Kline, U.S. 
application Ser. Nos. 10/742,721 and 10/778,477, two com-
monly-assigned non-provisional patent applications, disclose 
devices for collecting exhaled breath and are incorporated by 
reference herein in their entireties. 
[0014] Exhaled condensate is known to contain many mol-
ecules that can serve as markers of many lung diseases, as 
reviewed by Kharitinov et al. in 2001 (Biomarkers 7 (1):1-32, 
2002.). However, the concept of measuring lipopolysaccha-
ride in exhaled breath condensate for the purpose of diagnos-
ing Gram negative pneumonia or other Gram negative bacte-
rial infections has not been disclosed previously. 
SUMMARY OF THE INVENTION 
[0015] The present invention comprises a method for deter-
mining whether a subject has Gram negative bacterial pneu-
monia based on the presence oflipopolysaccharide in exhaled 
breath condensate collected from the subject. The present 
invention further comprises the collection devices utilized to 
collect exhaled breath condensate from both spontaneously 
breathing and mechanically ventilated subjects and the 
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devices utilized to determine whether lipopolysaccharide is 
present in the collected exhaled breath condensate. 
[0016] Broadly defined, the present invention, according to 
one aspect, is a method for diagnosing and monitoring intra-
pulmonary Gram negative bacterial infection in an air-breath-
ing vertebrate subject, including: collecting exhaled breath 
condensate from an air-breathing vertebrate subject; measur-
ing the concentration of lipopolysaccharide in the collected 
exhaled breath condensate; and determining whether the sub-
ject has an intrapulmonary Gram negative bacterial infection 
based on the measured concentration oflipopolysaccharide in 
the exhaled breath condensate. 
[0017] In features of this aspect, the intrapulmonary Gram 
negative bacterial infection is pneumonia; the intrapulmonary 
Gram negative bacterial infection is a bronchial infection; the 
method further includes selecting an antibiotic therapy in 
response to a positive determination that the subject has an 
intrapulmonary Gram negative bacterial infection; collecting 
exhaled breath condensate from an air-breathing vertebrate 
subject includes collecting exhaled breath condensate from a 
mammalian subject, and the method further includes moni-
toring the response of the mammalian subject to antibiotic 
therapy; the method further includes identifying the particu-
lar strain of the intrapulmonary Gram negative bacteria; iden-
tifying includes identifying the particular strain of intrapul-
monary Gram negative bacteria based upon a determination 
of the 0-saccharide portion of the lipopolysaccharide mol-
ecule; measuring the concentration of lipopolysaccharide 
includes measuring the concentration of lipopolysaccharide 
using the limulus amoebocyte lysate assay; a measured con-
centration oflipopolysaccharide of at least about 0.20 Endot-
oxin Units/mL (EU/mL) indicates the presence of a Gram 
negative bacterial infection; collecting exhaled breath con-
densate from an air-breathing vertebrate subject includes col-
lecting the expired breath condensate from a spontaneously 
breathing subject; collecting exhaled breath condensate from 
an air-breathing vertebrate subject includes collecting the 
expired breath condensate from a mechanically ventilated 
subject; and collecting exhaled breath condensate from an 
air-breathing vertebrate subject includes utilizing an exhaled 
breath condensate collection device comprising a chamber 
having inner walls that may be cooled to a temperature of 
about 32 degrees Fahrenheit and below to promote conden-
sation. 
[0018] The present invention, according to another aspect, 
is a method for diagnosing and monitoring intrapulmonary 
Gram negative bacterial infection in an air-breathing verte-
brate subject, including: collecting exhaled breath conden-
sate from an air-breathing vertebrate subject; providing a 
reaction chamber, wherein said reaction chamber has a reac-
tion reagent disposed therein; delivering at least a portion of 
the collected exhaled breath condensate to the reaction cham-
ber; and determining whether the subject has an intrapulmo-
nary Gram negative bacterial infection based on a physical 
change that occurs when the at least a portion of the collected 
exhaled breath condensate is delivered to the reaction cham-
ber, wherein said physical change is caused by the presence of 
lipopolysaccharide in the exhaled breath condensate. 
[0019] In features of this aspect, the reaction reagent 
includes a limulus amoebocyte lysate, a chromogenic sub-
strate and/or a fluorogenic substrate; the reaction reagent 
includes a chemical that liberates heat through an exothermic 
reaction upon delivery of the at least a portion of the exhaled 
breath condensate; the physical change is the formation of a 
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gel; the method further includes visually matching a color 
change in the reaction chamber to a standard, wherein said 
standard comprises a printed strip of color patches of increas-
ing hue intensity, and wherein each color patch corresponds 
to increasing concentrations of lipopolysaccharide, respec-
tively; a hue intensity corresponding to a concentration of 0.2 
endotoxin units per milliliter indicates the presence of an 
intrapulmonary Gram negative bacterial infection; collecting 
exhaled breath condensate from an air-breathing vertebrate 
subject includes collecting the expired breath condensate 
from a spontaneously breathing subject; collecting exhaled 
breath condensate from an air-breathing vertebrate subject 
includes collecting the expired breath condensate from a 
mechanically ventilated subject; collecting exhaled breath 
condensate from an air-breathing vertebrate subject includes 
utilizing an exhaled breath condensate collection device com-
prising a chamber having inner walls that may be cooled to a 
temperature of about 32 degrees Fahrenheit and below to 
promote condensation; and delivering at least a portion of the 
exhaled breath condensate comprises injecting at least of 
portion of the exhaled breath condensate into the reaction 
chamber via a hypodermic needle. 
[0020] The present invention, according to another aspect, 
is a method for diagnosing and monitoring intrapulmonary 
Gram negative bacterial infection in an air-breathing verte-
brate subject, including: collecting exhaled breath conden-
sate from an air-breathing vertebrate subject; providing a 
reaction chamber with an interior surface, wherein said reac-
tion chamber has a material that binds lipopolysaccharide 
disposed therein; delivering at least a portion of the collected 
breath condensate to the reaction chamber; washing the reac-
tion chamber with a buffer; delivering a reaction reagent to 
the reaction chamber; and determining whether the subject 
has an intrapulmonary Gram negative bacterial infection 
based on a physical change that occurs when the at least a 
portion of the collected exhaled breath condensate is deliv-
ered to the reaction chamber, wherein said physical change is 
caused by the presence of lipopolysaccharide in the exhaled 
breath condensate. 
[0021] In features ofthis aspect, the reaction reagent com-
prises a chromogenic substrate and/or a fluorogenic substrate; 
the binding material is an antibody that binds a specific spe-
cies of lipopolysaccharide; the antibody is disposed on the 
interior surface of the reaction chamber; the binding material 
is an insoluble polymer; the binding material is embedded in 
a matrix surface disposed within the reaction chamber; the 
method further includes visually matching a color change in 
the reaction chamber to a standard, wherein said standard 
comprises a printed strip of color patches of increasing hue 
intensity, and wherein each color patch corresponds to 
increasing concentrations of lipopolysaccharide, respec-
tively; a hue intensity corresponding to a concentration of 0.2 
endotoxin units per milliliter indicates the presence of an 
intrapulmonary Gram negative bacterial infection; collecting 
exhaled breath condensate from an air-breathing vertebrate 
subject includes collecting the expired breath condensate 
from a spontaneously breathing subject; collecting exhaled 
breath condensate from an air-breathing vertebrate subject 
includes collecting the expired breath condensate from a 
mechanically ventilated subject; collecting exhaled breath 
condensate from an air-breathing vertebrate subject includes 
utilizing an exhaled breath condensate collection device com-
prising a chamber having inner walls that may be cooled to a 
temperature of about 32 degrees Fahrenheit and below to 
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promote condensation; delivering at least a portion of the 
exhaled breath condensate comprises injecting at least of 
portion of the exhaled breath condensate into the reaction 
chamber via a hypodermic needle. 
[0022] The present invention, according to another aspect, 
is a method for diagnosing and monitoring intrapulmonary 
Gram negative bacterial infection in an air-breathing verte-
brate subject, including: collecting exhaled breath conden-
sate from an air-breathing vertebrate subject in a collection 
device having a narrow tube; inserting a fibrous plug impreg-
nated with enzymes that cause gelation upon exposure to 
lipopolysaccharide into the narrow tube; introducing at least 
a portion of the collected exhaled breath condensate sample 
into the narrow tube to wet the fibrous plug; and determining 
whether the subject has an intrapulmonary Gram negative 
bacterial infection based on the amount of gelation that 
occurs in the narrow tube, wherein said gelation is caused by 
the presence oflipopolysaccharide in the exhaled breath con-
densate. 
[0023] In features ofthis aspect, the fibrous plug is impreg-
nated with enzymes from limulus amoebocyte lysate; the 
method further includes providing a syringe disposed within 
the collection device, said syringe having a manometer dis-
posed on one side thereof for measuring hydraulic pressure; 
and the narrow tube is a hypodermic needle disposed at the 
end of the syringe. 
[0024] The present invention, according to another aspect, 
is a device for collecting exhaled breath condensate from a 
subject breathing with the assistance of a mechanical venti-
lation circuit, including: a mechanical ventilation circuit for 
facilitating breathing of the subject, wherein the mechanical 
ventilation circuit includes an expiratory flow tube that serves 
as a conduit for removing exhaled breath of the subject; a 
central chamber having an interior, wherein said central 
chamber may be cooled to a temperature of about 32 degrees 
Fahrenheit and below to promote condensation; a breath input 
assembly, disposed at one end of the central chamber, in fluid 
communication with the interior of the central chamber and 
the expiratory flow tube, whereby the breath input assembly 
connects the expiratory flow tube and the central chamber; an 
exit assembly, disposed at the other end of the central cham-
ber, in fluid communication with the interior of the central 
chamber; and a vacuum device connected to the exit assembly 
for collecting exhaled breath condensate from the central 
chamber. 
[0025] The present invention, according to another aspect, 
is a breath condensate collection device, including: a central 
chamber having an interior and first and second opposing 
ends; a breath input assembly in fluid communication with 
the interior of the central chamber; and an exit assembly in 
fluid communication with the interior of the central chamber, 
wherein the exit assembly includes a narrow tube, said narrow 
tube having a fibrous plug disposed therein, said plug being 
impregnated with a reaction reagent that causes gelation upon 
exposure to lipopolysaccharide. 
[0026] In features of this aspect, the plug is a fiber matrix 
impregnated with enzymes from a limulus amoebocyte; and 
the device further includes a plunger assembly having a pis-
ton and a handle, wherein the piston is slidably disposed in the 
interior of the central chamber and wherein the handle 
extends from the first end of the central chamber so as to 
permit the piston to be moved within the central chamber, 
whereby the collected breath condensate may contact the 
fibrous plug disposed within the narrow tube. 
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[0027] The present invention, according to another aspect, 
is a reaction chamber assembly for measuring the concentra-
tion of lipopolysaccharide in exhaled breath condensate, 
including: a reaction chamber; a delivery port for delivery of 
the exhaled breath condensate into the reaction chamber; a 
reaction reagent to react with lipopolysaccharide present in 
the exhaled breath condensate; and a viewing portion to allow 
for visible detection of a physical change in the reaction 
chamber. 
[0028] In features of this aspect, the delivery port is a re-
sealable cover that may be punctured with a hypodermic 
needle for delivery of the exhaled breath condensate; the 
viewing portion is a transparent wall; the reaction chamber 
further includes an interior surface, and a lipopolysaccharide-
immobilizing agent is bound to at least a portion of the inte-
rior surface of the reaction chamber; the lipopolysaccharide-
immobilizing agent is selected from the group consisting of 
monoclonal antibodies, polyclonal antibodies, polymyxin 
antibiotic, lipopolysaccharide-binding protein and limulus 
anti-lipopolysaccharide factor; the reaction chamber further 
includes a chemical disposed within the reaction chamber, 
wherein the chemical liberates heat upon hydration, whereby 
a temperature in the range of 34 to 43 degrees Celsius is 
achieved for a period of 15 to 30 minutes upon hydration of 
the chemical; the chemical is a salt in a semipermeable 
matrix; the chemical is a salt in crystalline form; and the 
chemical is sodium thiosulfate pentahydrate. 
[0029] The present invention, according to another aspect, 
is a test kit cartridge for detecting the presence oflipopolysac-
charide in exhaled breath condensate, including: a housing; a 
test module disposed within the housing, said test module 
utilizing a user-initiated chemical reaction to detect the pres-
ence oflipopolysaccharide in the exhaled breath condensate; 
and a positive control module disposed within the housing 
adjacent to the test module, said positive control module 
having lipopolysaccharide disposed therein for showing a 
definite positive result for the presence oflipopolysaccharide 
for comparison with the test module. 
[0030] In features of this aspect, a chemical disposed in the 
housing provides a controlled exothermic reaction, whereby a 
temperature between 34 and 43 degrees Celsius is achieved 
for a period of 15 to 30 minutes; the chemical is sodium 
thiosulfate pentahydrate; each module of the test kit includes 
a re-sealable injection port, a reaction well, a fluid connection 
between the reaction well and the injection port, a first one-
way valve disposed in the fluid connection, an exit tube pro-
viding an outlet for the reaction well, and a second one-way 
valve disposed in the exit tube; each reaction well includes a 
clear covering adapted to allow visual determination of physi-
cal change; each reaction well includes an insoluble poly-
meric lipopolysaccharide-binding matrix; the positive con-
trol module reaction well includes lipopolysaccharide from a 
suitable species of Gram negative bacteria; the test kit car-
tridge further includes a chromogenic substrate, reconstituted 
from a reaction chamber; the test kit cartridge further includes 
a color strip, the color strip having color patches ofincremen-
tally increasing color intensity, wherein each color patch cor-
responds to a prescribed range of endotoxin units to allow for 
visual comparison against a color change in the reaction 
wells; the housing is formed from a polymer; the polymer is 
plastic. 
[0031] The present invention, according to another aspect, 
is a device for collecting exhaled breath condensate from a 
subject. The device comprises a plunger assembly and a stop-
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per. The stopper is connected to the plunger disk of the 
plunger assembly by a plurality of support pins and is con-
figured for sealing engagement within the nose section of the 
exit assembly when the plunger assembly is depressed, 
whereby the collected breath condensate may be expelled 
from the central chamber via the hypodermic needle. 
[0032] Further areas of applicability of the present inven-
tion will become apparent from the detailed description pro-
vided hereinafter. It should be understood that the detailed 
description and specific examples, while indicating the pre-
ferred embodiment of the invention, are intended for purposes 
of illustration only and are not intended to limit the scope of 
the invention. 
BRIEF DESCRIPTION OF THE DRAWINGS 
[0033] Further features, embodiments, and advantages of 
the present invention will become apparent from the follow-
ing detailed description with reference to the drawings, 
wherein: 
[0034] FIG. 1 is a schematic diagram of the basic structure 
of lipopolysaccharide; 
[0035] FIG. 2 is a side cross-sectional schematic view of a 
breath condensate collection device in accordance with a first 
preferred embodiment of the present invention; 
[0036] FIG. 3A is a partial side cross-sectional schematic 
view of the breath condensate collection device ofFIG. 2 with 
the plunger assembly in a partially depressed position; 
[0037] FIG. 3B is a partial side cross-sectional schematic 
view of the breath condensate collection device ofFIG. 2 with 
the plunger assembly in a fully depressed position; 
[0038] FIG. 4 is a partial side cross-sectional view of a 
breath condensate collection device in accordance with a 
second preferred embodiment of the present invention; 
[0039] FIG. 5 is a side cross-sectional schematic view of a 
breath condensate collection device in accordance with a 
third preferred embodiment of the present invention; 
[0040] FIG. 6 is a schematic illustration of an alternative 
ventilation system implementation of the preferred embodi-
ments of the present invention; 
[0041] FIG. 7 is a side cross-sectional schematic view of a 
reaction chamber device suitable for use with the collection 
devices of FIGS. 2, 4 and 5; 
[0042] FIG. 8 is a top view of the reaction chamber device 
of FIG. 7; 
[0043] FIG. 9 is a side perspective view of a first alternative 
reaction chamber device; 
[0044] FIGS. lOA-lOD are partial side cross-sectional 
views of the first alternative reaction chamber device of FIG. 
9; 
[0045] FIG. 11 is a perspective view of a test kit incorpo-
rating a second alternative reaction chamber device; 
[0046] FIG. 12 is a side cross-sectional view of the test 
module of FIG. 11, taken along line 12-12; 
[0047] FIG. 13 is a side cross-sectional view of the positive 
control module of FIG. 11, taken along line 13-13; 
[0048] FIG. 14 is a partial side cross-sectional view of a 
breath condensate collection device in accordance with a 
fourth preferred embodiment of the present invention; 
[0049] FIG. 15 is an enlarged partial side cross-sectional 
view of the needle of FIG. 14; 
[0050] FIG. 16 is a cross-sectional view of a breath con-
densate collection device in accordance with another embodi-
ment of the present invention. 
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[0051] FIG. 17 is an enlarged cross-sectional view of a 
stopper in the nose of the breath condensate collection device 
of FIG. 16. 
[0052] FIG. 18 is an enlarged side view of a support pin as 
shown in FIG. 16. 
[0053] FIG. 19 is a top view of a stopper as shown in FIG. 
16. 
[0054] FIG. 20 is a scatter plot graph illustrating the mea-
sured endotoxin concentrations for patients in each of three 
study groups. 
DETAILED DESCRIPTION OF THE INVENTION 
[0055] The method of the present invention utilizes exhaled 
breath condensate to determine whether LPS is present in the 
exhaled breath condensate and thus determine whether a sub-
ject has an intrapulmonary. Gram negative bacterial infection. 
The present application is directed toward diagnosing Gram 
negative bacterial pneumonia; however, one of ordinary skill 
in the art will understand that the present invention may be 
utilized to detect any Gram negative bacterial infection, 
which is also useful. A patient diagnosed with a Gram nega-
tive bacterial infection will be treated with the same antimi-
crobial therapy whether the diagnosis is Gram negative pneu-
monia or another Gram negative bacterial infection. One of 
ordinary skill in the art will understand that while the meth-
odology for detecting LPS, as described herein, is the limulus 
amoebocyte lysate assay, any methodology for detecting the 
presence of LPS, including, but not limited to the ELISA 
assay and the rabbit pyrogen test, may be utilized in the 
present invention. 
[0056] Intrapulmonary LPS content can vary based upon 
the health of the lung in the subject providing a breath con-
densate sample. Generally, a concentration ofLPS in exhaled 
breath condensate of at least about 0.2 EU/mL corresponds to 
a clinical test positive threshold, indicating the presence of 
Gram negative bacterial infection in the lungs. An EU is an 
endotoxin unit. The USDA recommends reporting the con-
centration of endotoxin in endotoxin units because an EU can 
be standardized, unlike typical mass concentrations, which 
cannot be standardized because of the variable potency of 
lipopolysaccharide, which varies between bacteria type. An 
endotoxin unit refers to the amount of LPS reactivity con-
tained in the unknown sample. This amount of reactivity is 
determined by interpolation from a standard curve, which is 
derived from an FDA-approved strain of E-Coli that has a 
known amount ofLPS reactivity. 
[0057] It is possible for the device used to collect exhaled 
breath condensate to contain a "background" level ofLPS due 
to naturally occurring LPS. In order to account for this back-
ground concentration, a "mock" standard may be conducted 
with the device that will be used for exhaled breath collection 
by instilling LPS-free water through the device. The LPS 
concentration values found in the water sample may then be 
subtracted from the LPS concentration values found in breath 
condensate samples to remove the background "noise" of the 
system. The background concentration of LPS will vary 
depending on the device being used for collection. 
[0058] A breath condensate collection device, several 
examples of which are described herein below in further 
detail, may be used to collect exhaled breath condensate from 
a patient presenting symptoms synonymous with Gram nega-
tive bacterial pneumonia for detection of LPS content in 
amounts indicating infection. 
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[0059] Referring now to the drawings, in which like numer-
als represent like components throughout the several views, 
the preferred embodiments of the present invention are next 
described. The following description of the preferred 
embodiment(s) is merely exemplary in nature and is in no 
way intended to limit the invention, its application, or uses. 
[0060] FIG. 1 is a schematic diagram of the basic structure 
oflipopolysaccharide. This structure is found in the cell wall 
of all Gram negative bacteria. Lipopolysaccharide (also 
referred to as endotoxin) is a complex glycolipid, weighing 
approximately 10 Kd. The basic structure oflipopolysaccha-
ride involves three relatively well defined regions and is simi-
lar in all gram-negative bacteria. These regions are an 0-an-
tigen portion, a core polysaccharide and lipid A. The 
0-antigen portion is composed of repeating polysaccharide 
units, each having 2-6 saccharides. The 0-antigen portion 
varies considerably among Gram negative species and can 
thus serve as a marker of individual bacterial species, based 
upon binding of specific monoclonal antibodies. The core lies 
between the 0-antigen portion and lipid A and is a branching 
polysaccharide having representative sugars such as glucose, 
N-acetylglucosamine and galactose. Unlike the 0-antigen 
portion, there is only minor variation throughout the core 
region with the structure being highly conserved in the inner 
core region proximal to lipid A. The most highly conserved 
portion of the LPS molecule is lipid A, a disaccharide diphos-
phate, to which long-chain fatty acids are attached. The lipid 
A portion of the molecule confers toxicity in virtually all 
complex eukariotic organisms. In, humans, this includes 
induction of cytokines, fever, leukocytosis, recruitment and 
activation of leukocytes, vascular damage, vasodilation, 
intravascular coagulation and organ damage. 
[0061] One accepted method of detecting and quantifying 
LPS takes advantage of the toxic effect ofLPS on the aqueous 
extract of amoebocytes from the horsehoe crab, limulus 
polyphemus. The term "amoebocytes," as used in the present 
application, refers to blood cells. This method, known gener-
ally as the limulus amoebocyte lysate ("LAL") assay, is 
described in U.S. Pat. Nos. 4,322,217; 5,310,657 and 5,702, 
882. Other recognized methods include the in-vivo rabbit 
pyrogen assay and the human pyrogen assay, which are well 
known to those skilled in the art and thus, will not be dis-
cussed in detail herein. 
[0062] Briefly summarized, LAL forms a coagulen gel 
when incubated with LPS, which enables the detection of 
small quantities ofLPS. More specifically, in the LAL assay, 
LPS activates an enzyme, commonly known as factor C, 
which is contained in the amoebocytes. Activated factor C, in 
turn, activates factor B by hydrolyzing a specific site of factor 
B. Activated factor B activates a proclotting enzyme to con-
vert it into a clotting enzyme. The clotting enzyme then 
cleaves coagulogen (coagulant protein, molecular weight: 
19,723) at specific sites (i.e., Arg8 -Thr19 andArg46-Gly47) to 
cause gelation of the mixture. In addition, co-factors such as 
salts of calcium, magnesium and phosphate or other organic 
compounds such as hydroxymethyl ("TRIS") aminomethane 
buffer must be present to maintain a pH between 6.5 and 7.4, 
enabling the clotting enzyme to function. 
[0063] Various techniques have been utilized to detect LPS 
based on the formation of a coagulen gel in the LAL assay. 
Some are endpoint assays that simply wait for the formation 
of a gel to determine the presence of LPS. Others are more 
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complex and use kinetic turbidimetric methods to measure 
the increase in turbidity as coagulation occurs in the LAL 
assay. 
[0064] An alternative assay methodology using chromoge-
nic or fluorogenic substrates has also been used to detect LPS 
in order to overcome difficulties associated with accurately 
determining gel formation. This alternative methodology 
relies on the clotting enzyme that was formed in the above 
cascade reaction hydrolyzing an amide bond in a synthetic 
substrate. The synthetic substrate may be covalently attached 
to a marker molecule or compound, which is liberated when 
hydrolyzed by the clotting enzyme. The liberated marker may 
then be detected by colorimetry or spectrophotometry, thus 
indicating the presence of LPS. Examples of synthetic sub-
strates may include, but are not limited, t-butoxycarbonyl-
leucyl-glycyl-arginine-paranitroanilide (N-t-Boc-Leu-Gly-
Arg-pNA), N-t-Boc-Val-Leu-Gly-Arg-pNA (SEQ ID NO: 1), 
benzyloxycarbonyl-leucyl-glycyl-arginine-paranitroanilide 
(Z-Leu-Gly-Arg-pNA), Boc-Ile-Glu-Gly-Arg-pNA (SEQ ID 
NO: 2), Boc-Val-Ser-Gly-Arg-pNA (SEQ ID NO: 3) or Boc-
Ser-Gly-Arg-pNA, all of which liberate paranitroaniline, 
which imparts a yellow color to the reaction mixture. Specific 
examples of chromogenic assays are described in Ling, U.S. 
Pat. No. 6,645,724, and Tamura et al., U.S. Pat. No. 5,702, 
882. 
[0065] It is also possible to synthesize the enzyme needed 
for the clotting cascade in-vitro by recombinant biotechnol-
ogy rather than obtaining the enzyme from a horseshoe crab. 
Such synthesized enzyme can be used to detect and quantify 
LPS in an unknown solution using the chromogenic method. 
[0066] Other alternate methods of capturing and detecting 
LPS are also known. An LPS binding material, e.g., poly-
myxin antibiotics or resins, in the form of an insoluble matrix 
polymer, may be affixed to a support for immobilization and 
subsequent detection of LPS by any of the above described 
turbidimetric, chromogenic or fluorogenic methods. In addi-
tion, LPS may be immobilized by any number of antibodies 
with a high affinity for LPS. Antibodies have a Y-shaped 
structure and include two basic units. The first unit is the 
fragment-antigen binding portion ("Fab") and it binds an 
antigen, in this situation, LPS. The second unit is the frag-
ment-crystallized portion ("Fe"). The Fe unit can function as 
a handle to dock the antibody to an immobile surface. Poten-
tially useful antibodies include, but are not limited to, poly-
clonal or monoclonal antibodies, such as lipid-A reactive 
monoclonal antibody ("HA-1 A") and murine anti-endotoxin 
immunoglobulin M ("E5"), lipopolysaccharide-binding pro-
tein ("LBP") and related proteins, bacteriocidal/permeability 
increasing protein ("BPI") and limulus anti-LPS factor 
("LALF"). 
[0067] A method utilizing enzyme-linked immunoassay 
technology is also known in which various selected matrix-
bound antibodies may be used to capture and detect specific 
endotoxins and therefore specific bacteria types. Examples of 
endotoxin from bacteria that may be detected, include, but are 
not limited to, Escherichia, Bordetilla, Branhamella, Salmo-
nella, Haemophilus, Klebsiella, Proteus, Enterobacter, 
Pseudomonas, Pasteurella, Acinetrobacter, Chlamydia and 
Neisseria and in general any bacteria whose LPS is capable of 
binding to the selected antibody. 
[0068] It is further recognized that the presence of ~-1,3 
glucans (~-D-glucans) may also activate the above-described 
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clotting cascade. One of ordinary skill in the art will under-
stand that specific measures may be undertaken to limit this 
false positive effect. 
[0069] The present invention includes several collection 
devices designed to allow rapid (e.g., less than 30 minutes), 
noninvasive collection of exhaled breath condensate ("EBC") 
from a spontaneously breathing subject or a patient receiving 
mechanical ventilation, followed by one-step quantitative or 
semi-quantitative analysis of the condensate for the concen-
tration of LPS. In spontaneously breathing subjects, the 
exhaled condensate may generally be collected via a mouth-
piece held by the lips; however, in patients with severe respi-
ratory distress, the sample may be collected by fitting the 
patient with an airtight, snug-fitting facemask that allows the 
delivery of oxygen, while allowing the diversion of exhaled 
gases and aerosol into a condensing chamber such as those 
described below. 
[0070] In general, the breath condensate collection devices 
each comprise a collection chamber that has sterile, LPS-free 
inner walls that can be cooled to a temperature below 32° F. to 
allow condensation of exhaled breath. These breath conden-
sate collection devices are preferably disposable and light-
weight. Each includes coaxial chambers with an interposed 
area containing coolant that can be chilled externally or via an 
internal endothermic reaction. Such breath condensate col-
lection devices are generally described in the aforementioned 
commonly-developed and commonly-assigned U.S. patent 
application Ser. Nos. 10/742,721 and 10/778,477. However, 
the devices described and illustrated herein have additional 
novel and useful features not included in any prior art devices. 
[0071] FIG. 2 is a side cross-sectional schematic view of a 
breath condensate collection device 10 in accordance with a 
preferred embodiment of the present invention. This configu-
ration may be particularly appropriate for use with coopera-
tive humans. The breath condensate collection device 10 
includes a double-walled syringe 20 anda breath input assem-
bly 50. The innerwall 22 of the syringe 20 defines a cylindri-
cal central chamber 24 in which is fitted a plunger assembly 
25 that includes a piston 26, a rubber gasket 28 and a handle 
30 extending from one end of the syringe 20. The outer wall 
32 is arranged around the inner wall 22 in such a way as to 
create a narrow space between the inner and outer walls 22, 
32. During manufacture, the space between the inner and 
outer walls 22, 32 may be filled with a jacket of coolant 
material 34, and the outer wall 32 may then be sealed to the 
inner wall 22 to prevent leakage. In a preferred embodiment, 
water may be used as the coolant material 34, but it should be 
clear that other materials may likewise be used, such as poly-
ethylene glycol ("PEG") and the like. 
[0072] The syringe 20 further includes an inlet 36, an outlet 
38 and a pair of one-way valves 40, 42. The first valve 40 is an 
intake valve that may be disposed in or adjacent to the inlet 36, 
while the second valve 42 is an exit valve that may be dis-
posed in or adjacent to the outlet 38 in order to facilitate the 
passage of exhaled air through the central chamber 24 in only 
a single direction. The outlet 38 is preferably disposed at the 
end opposite the plunger handle 30 in order to permit mate-
rials collected within the central chamber 24 to be expressed 
through the outlet 38 by the piston 26. The outlet 38 may be 
disposed in the end of a nozzle 39 that is in the form of a 
nipple. The nozzle 39 may also include a fitting, such as the 
female portion of a luer lock, at its distal end. Such a fitting 
may permit a protective cover or other accessory to be 
attached to the nozzle 39. The valves 40, 42 are illustrated 
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only schematically in the various drawings, but they may, for 
example, include two or three self-sealing leaves formed from 
plastic or another deformable polymer. The design of such 
valves would be apparent to those of ordinary skill in the art. 
[0073] The piston 26 includes a tip or protrusion 27 of 
dimensions and shape suitable for fitting snugly into the 
nozzle 39 when the plunger assembly 25 is fully depressed. 
The tip 27 includes a plurality of radial conduits 31 arranged 
around the base of the tip 27 and connecting to a hollow 
central shaft or conduit 33 in which is disposed a needle 35, 
such as a hypodermic needle. The radial conduits 31 and the 
central conduit 33 are preferably between about 1 and 2 mm 
in diameter, and the outside diameter of the needle 35 is 
likewise preferably between about 1 and 2 mm in diameter in 
order to fit snugly into the central conduit 33. 
[0074] Further, because the piston 26 fills one end of the 
syringe 20 and the outlet 38 is disposed in the opposite end, 
the inlet 36 is preferably arranged to penetrate both the inner 
and outer walls 22, 32 on the side of the syringe 20. In order 
to cause the most interaction between exhaled air passing 
through the central chamber 24 and the inner surfaces 44 of 
the inner wall 22, the inlet 36 is preferably disposed as close 
to the piston 26 as possible; however, it will be clear that other 
arrangements of these components are likewise possible 
without departing from the scope of the present invention. 
[0075] The breath input assembly 50 includes a mouthpiece 
52, a filter 54 and any tubing 56 necessary to guide exhaled 
breath from the mouthpiece 52 to the inlet 36 of the syringe 
20. The mouthpiece 52 is of suitable size and shape so as to 
permit comfortable contact with the mouth area of a patient. 
The filter 54, which may comprise a polymer material having 
perforations or successive intrusions therein, may be 
arranged within the tubing 56 between the mouthpiece 52 and 
the syringe inlet 36 to prevent saliva and other liquid or solid 
matter of a minimum size from passing therethrough and into 
the syringe 20. Saliva may be further prevented from reaching 
the central chamber 24 by arranging the breath input assem-
bly 50 beneath the syringe 20, so that air passing through the 
breath input assembly 50 moves upward. In this arrangement, 
the effect of gravity on the saliva and other liquid or solid 
matter helps to prevent such matter from passing up into the 
central chamber 24, as it instead tends to collect in the tubing 
56. 
[0076] The tubing 56 is preferably configured so as to avoid 
interference between the mouthpiece 52, or any other part of 
the tubing 56, and the operation of the plunger assembly 25, 
as such operation is described herein. More preferably, the 
mouthpiece 52 is oriented to be generally parallel with the 
syringe 20 and the plunger assembly 25 therein, or in other 
words, the mouthpiece 52 is oriented in parallel to the main 
axis defined by the syringe 20. In this orientation, exhaled 
breath may be received from a patient without causing inter-
ference to the operation of the plunger assembly 25, and 
condensate formed on the inside of the syringe 20 as the 
patient uses the device 10 will tend to drain downward toward 
the outlet 38. 
[0077] The dimensions of the device 10 are chosen so that 
a sufficient volume of condensate may be collected in a rela-
tively short period of time using a device 10 that is small and 
light enough to be easily held by a patient or attendant and that 
does not require the patient to change his breathing patterns. 
The walls 22, 32 and other structures of the device 10 are 
preferably constructed of a material that tends not to bind to 
proteins, such as platinum-cured silicon. Other suitable mate-
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rials may include, but are not limited to, glass, plastic, poly-
ethylene, polycarbonate, or polyvinyl or other synthetic poly-
mer. The plunger assembly 25 is likewise preferably 
constructed from a non-protein-binding material, but may be 
constructed from any suitable inert material including, but not 
limited to, plastic, vinyl, polyethylene, rubber, platinum-
cured silicon or a fluorine-containing polymer. In addition, 
TEFLON®, which is a fluorine-containing polymer and is a 
registered trademark owned by E.I. Du Pont De Nemours and 
Company Corporation of Wilmington, Del., may be used. In 
a preferred embodiment, the syringe 20 is between 10 and 20 
cm long with a diameter of between 2 and 5 cm. The thickness 
of the coolant jacket 34 may be between 1 and 10 mm, and the 
sample volume, expressed from a single use, is preferably 
between 100 µL and 1000 µL, although it may be possible to 
obtain useful results from samples as small as 25 µL. 
[0078] The plunger assembly 25 is modified relative to the 
plunger assemblies disclosed in prior applications through 
the inclusion of the hypodermic needle 35, described previ-
ously, or a similar structure. This modification facilitates the 
sterile delivery of condensate into a specialized reaction 
chamber device, examples of which are described below. The 
needle 35 is centrally disposed in the central conduit 33 of the 
piston tip 27, and the interior of the needle 35 is arranged in 
fluid communication with the radial conduits 31 in the tip 27 
for a purpose made evident hereinbelow. 
[0079] In operation, one or more syringes 20 are first stored 
in a refrigeration device, such as a conventional household or 
commercial freezer, that is capable oflowering the tempera-
ture to approximately 0° F., thus freezing the jacket of coolant 
material 34 contained between the inner and outer walls 22, 
32 of the syringe 20. When a patient is to be examined, a 
single syringe 20 is first withdrawn from the freezer. If the 
breath input assembly 50 or mouthpiece 52 is stored sepa-
rately from the rest of the device 10, then the device 10 is 
assembled for use by coupling the various components 
together. Next, the patient positions the mouthpiece 52 in a 
sealed relationship to his mouth area and exhales into the 
mouthpiece 52. The exhaled breath is guided through the 
tubing 56 and into the central chamber24 via the inlet 36. The 
intake valve 40 is forced open by positive pressure, but in the 
absence of such pressure, it prevents air within the central 
chamber 24 from escaping through the inlet 36. The exhaled 
breath then exits through the outlet 38, on the end of the 
chamber 24 opposite the intake end via the needle 35. The exit 
valve 42 permits air to pass out of the central chamber 24 only 
when positive pressure exists on the cylinder side of the valve 
42, while in the absence of such pressure, the valve 42 pre-
vents ambient air from entering the central chamber 24 via the 
outlet 38. 
[0080] As the patient exhales through the device 10, the 
moisture in the exhaled breath begins to condense on the inner 
surfaces 44 of the central chamber 24. Because of the 
depressed temperature of the coolant 34 and the syringe 20, 
the condensate may freeze immediately on the inner surface 
44. The diameters of the nozzle 39 and the needle 35 are small 
enough to cause resistance to the exhalation of the patient. 
The diameters may be preferably chosen so as to slow the rate 
of expiration until each exhalation requires approximately 5 
seconds to complete or until a resistance of up to about 5 cm 
of water pressure is provided. It will be apparent to one of 
ordinary skill in the art that the nozzle 39 may alternatively be 
fitted with a positive end-expiratory pressure valve (a "PEEP" 
valve), which has a dial to vary the resistance to exhalation. 
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PEEP valves are commercially available from Life Assist Inc, 
Rancho Cordova, Calif. This modification would increase the 
amount of time for exhaled breath to equilibrate with the 
inside surfaces 44 of the central chamber 24. 
[0081] As the patient continues to exhale through the 
device 10, the frozen coolant 34 disposed in the space 
between the inner wall 22 and outer wall 32 of the device 10 
begins to melt. The composition, volume and thickness of the 
coolant jacket 34 surrounding the central chamber 24 is pref-
erably calibrated such that the coolant 34 begins to melt after 
approximately 10-15 exhalations by the patient. Once the 
coolant 34 melts or thaws after the desired number of exha-
lations, the condensate likewise can begin to melt. Once the 
condensate is melted, the plunger assembly 25 may be 
depressed to express the collected condensate sample through 
the outlet 38. 
[0082] FIGS. 3A and 3B are partial side cross-sectional 
schematic views of the breath condensate collection device 
10 of FIG. 2 with the plunger assembly 25 in a partially 
depressed position and a fully depressed position, respec-
tively. As the plunger assembly 25 is depressed, the needle 35 
is forced through the outlet 38. Meanwhile, as the volume of 
the space between the piston 26 and the outlet 38 shrinks, 
condensate is forced through the radial conduits 31 to the 
central conduit 33 and from there into the hypodermic needle 
35. The condensate is then ready for ejection into a suitable 
reaction chamber device, several examples of which are 
described below with reference to FIGS. 7-13. Ejection may 
be facilitated by complete depression of the plunger assembly 
25. A clip assembly may be provided at the opposite end of the 
syringe 20 in order to capture the handle 30 of the plunger 
assembly 25, thereby providing an indication to the user that 
the plunger assembly 25 has been fully depressed. Finally, 
once the EBC has been collected and ejected via the needle 35 
in accordance with the test procedures described hereinbe-
low, the entire device 10 may be disposed of according to 
conventional waste disposition procedures. 
[0083] FIG. 4 is a partial side cross-sectional view of a 
breath condensate collection device 60 in accordance with a 
second preferred embodiment of the present invention. Like 
the first embodiment, this breath condensate collection device 
60 includes a double-walled syringe 62, which includes a 
central chamber 24, a plunger assembly 65, a rubber gasket 28 
and a handle 30, and a breath input assembly (not shown). The 
body of the syringe 62, including the central chamber 24 and 
the various components thereof, are similar to those of the 
first syringe 20 with several significant exceptions. First, the 
outlet 38 of the first embodiment is replaced with an bleed 
port 68, approximately 1 mm in diameter, penetrating the 
inner and outer walls 22, 32 of the syringe 62 near the distal 
end thereof. The bleed port 68 allows air to escape from the 
central chamber 24 as the plunger assembly is depressed but 
retains the EBC. Also, the plunger assembly 65 does not 
include a nipple-shaped tip on the face of the piston 66 or a 
needle extending therefrom. However, the face of the piston 
66 does have a slight conical shape, and the end of the central 
chamber 24 is correspondingly-shaped. Together, this con-
figuration may guide collected condensate to the outlet 38 
more efficiently. It will be apparent, however, that the nipple-
shaped tip 27 of the previous device 10 and the conical shape 
disclosed in the device of FIG. 4 are not mutually exclusive, 
and that the conical shape may easily be incorporated into the 
device of FIG. 2, i.e., by combining the nipple-shaped tip 27 
of FIG. 2 with the conical shape of FIG. 4. 
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[0084] Another difference between the first and second 
devices 10, 60 is that the second device includes a threaded 
nozzle 61 in which may be fixed a hypodermic needle 35. The 
needle 35 is similar to the needle 35 of the first device 10, but 
is fixed in the nozzle 61 rather than being mounted on the 
plunger assembly 65. The interior of the needle 35 is com-
municatively connected to the interior of the central chamber 
24. The needle 35 may be protected by a removable plastic 
covering 69 having a threaded fitting that facilitates easy 
connection and removal of the covering 69 from the threaded 
nozzle 61. When attached to the syringe 62, the covering 69 
preferably provides a relatively air-tight seal for a purpose 
described below. 
[0085] Use of this second device 60 is somewhat similar to 
that of the first device 10, although the covering 69 must be 
removed before the subject may breathe through the needle 
35. However, the modifications described above may make 
this device 60 better adapted to deliver a calibrated amount of 
condensate than the first device 10. Once the subject has taken 
a sufficient number of breaths through the device 60 to ensure 
that a minimum volume of condensate has been collected, the 
covering 69 may be replaced on the end of the syringe 62, and 
the plunger assembly 65 may be carefully depressed. 
Although the covering 69 effectively prevents gas or liquid 
from passing through the needle 35, the bleed port 68, which 
is of conventional design, permits egress of air and any excess 
condensate until the face of the piston 66 passes the calibra-
tion line 78. If desired, a cotton ball or other absorbent mate-
rial, and an appropriate support structure if desired, may be 
disposed over the bleed port 68 in order to prevent EBC from 
escaping to the environment. By holding the device 60 with 
the bleed port 68 oriented in an upward direction, most or all 
air may be removed from the central chamber 24, and a 
calibrated volume of condensate is left therein as measured by 
the calibration line 78. As shown in FIG. 4, the syringe 62 may 
use a single wall design in the region of the calibration line 78 
in order to make it easier to see the liquid contained therein. 
Preferably, the syringe 62 is calibrated to collect a volume of 
between 250 and 500 µL. The covering 69 may then be 
removed again and this calibrated volume may be delivered 
by the needle 35 into a suitable reaction chamber device. 
[0086] FIG. 5 is a side cross-sectional schematic view of a 
breath condensate collection device 80 in accordance with a 
third preferred embodiment of the present invention. It may 
be advantageous to fractionate exhaled breath into airway and 
alveolar components, to allow condensation to occur only 
from the portion of breath originating from the alveoli. This 
partitioning step may help distinguish lower tract lung infec-
tion from bronchitis.As described in the aforementioned U.S. 
patent application Ser. No. 10/778,477 to Kline, a device for 
collection of exhaled alveolar breath condensate may incor-
porate a gating mechanism actuated, for example, by a rise in 
the partial pressure of exhaled carbon dioxide. The breath 
condensate collection device 80 illustrated in FIG. 5 is an 
example of a device suitable for use in the preferred embodi-
ments of that device or in comparable devices. The device 80 
of FIG. 5 is similar to the device 10 of FIG. 2 except that the 
breath input assembly 50 of the first device 10 has been 
removed to permit the device 80 to be inserted into a housing 
such as that included in the device disclosed in U.S. patent 
application Ser. No. 10/778,477. The direction of airflow 
during the condensation process may also be reversed, as 
shown in FIG. 5, either to facilitate fluid communication from 
the gating mechanism or for other purposes, as will be appar-
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ent to those of ordinary skill in the art. In this case, the 
respective positions of the outlet 36 and inlet 38, and their 
respective one-way valves 81, 83, are now reversed with 
respect to the device 10 of FIG. 2. 
[0087] Although not illustrated herein, airflow reversal 
may also be applied to the device 60 shown in FIG. 4. Even 
with the airflow direction reversed, however, the condensate 
may still be delivered into a reaction chamber device via the 
hypodermic needle 35 as described with regard to either 
FIGS. 3A and 3B or FIG. 4. 
[0088] In the preceding embodiments, the respective 
devices 10, 60, 80 are designed for the collectionofEBC from 
spontaneously breathing subjects, where the subject exhales 
via a mouthpiece or facemask (not shown) into tubing that 
directs flow into the appropriate entry port, such as the ones 
diagrammed in FIG. 2 or FIG. 5. It would also be advanta-
geous for the present invention to be adapted to allow collec-
tion from patients being ventilated mechanically. In most 
hospitals, humans are ventilated against pressurized air, often 
enriched with oxygen and humidified with excess water 
vapor. This excess water vapor causes condensation to accu-
mulate in the outflow tubing that directs the exhaled breath 
away from the patient's lungs during the respiratory cycle. It 
is a standard practice for respiratory therapists to affix a small 
cylinder, of approximately 20-100 mL volume, to collect this 
condensate in the most dependent portion of the exhalation 
circuit. To take advantage of the present invention to diagnose 
Gram negative bacterial lung infection in a ventilated patient, 
an aliquot of the collected condensate may be analyzed for 
LPS content. In the simplest embodiment, a commercially 
available syringe of a type used for drug delivery (e.g., an 
insulin syringe) may be used to withdraw a set volume of 
condensate (e.g., 100-200 microliters) found in the conden-
sate reservoir in the exhalation line of the ventilation circuit, 
and this volume could be injected into a reaction chamber 
device, examples of which are described hereinbelow. 
[0089] FIG. 6 is a schematic illustration of an alternative 
ventilation system implementation of the preferred embodi-
ments of the present invention. Using the device 80 of FIG. 5 
as an example, collection from a ventilated patient may be 
facilitated by adding a vacuum system 92 to the outlet 36 of 
the device 80 and connecting a Y- or T-fitting 94 to the luer 
lock fitting, described previously, on the end of the nozzle 39. 
The Y- or T-fitting 94 is connected inline in the middle of the 
outflow path from the patient 96 to a conventional ventilator 
98. The outflow path includes two polyethylene tubes 102, 
104, the first of which is connected from a conventional 
endotracheal tube 100, or other patient interface, to the inlet 
of the Y- or T-fitting 94, and the second of which is connected 
between the outlet of the Y- or T-fitting 94 and a port such as 
the one usually provided on the outflow track of the ventilator 
110. A third polyethylene tube 106, is connected from the 
inflow track of the ventilator 110 to the endotracheal tube 100. 
Each polyethylene tube 102, 104, 106 may be of approxi-
mately 10-30 mm internal diameter and 1 meter or more in 
length. Together, such an apparatus allows the vacuum sys-
tem 92 to withdraw a continuous sidestream sample of 
exhaled breath through the collection device 80 until a suffi-
cient volume ofEBC is collected. The rate of aspiration by the 
pump of the vacuum system 92 may be set at approximately 
lOOmL/min. 
[0090] FIGS. 7 and 8 are a side cross-sectional schematic 
view and a top view, respectively, of one reaction chamber 
assembly 120 suitable for use with the collection devices 10, 
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60, 80 of FIGS. 2, 4 and 5. The reaction chamber assembly 
120 is designed to detect and quantify the amount of LPS 
present in the EBC. The assembly 120 resembles the general 
configuration of a sterile ampule that is commonly used to 
store drugs for injection. The assembly 120 may function 
both as a reaction chamber and a spectrophotometer cuvette 
to measure the percentage of transmission of visible light, 
which is proportional to the concentration of LPS in the 
sample. The assembly 120 is vacuum-sealed and includes a 
reaction chamber 122 and a plug 124, a retaining ring 126, 
and a protective cap 128. The reaction chamber 122 is pref-
erably made of glass or another transparent material, but may 
alternatively be made of a semi-transparent (translucent or 
other non-opaque) material if the chosen color or light change 
or phenomenon, described below, may be readily seen there-
through. The reaction chamber 122 preferably has a volume 
of approximately 0.5-1.0 mL. Although as shown the reaction 
chamber 122 is round, it will be apparent that the reaction 
chamber 122 can likewise be square or have another geomet-
ric shape to facilitate its insertion into a spectrophotometer, or 
can be altered to allow "retrofitting" into existing commercial 
laboratory assay systems. The reaction chamber 122 further 
includes a threaded male luer lock fitting 132 of similar size to 
that of the condensate collection devices 10, 80 described 
above. Of course, if a device 60 such as that disclosed in FIG. 
4 is utilized, then the luer lock fitting 132 may not be neces-
sary. 
[0091] The plug 124, which is preferably formed from rub-
ber, may be disposed in the top of the chamber 122 to main-
tain a sealed, sterile, pyrogen-free environment inside the 
chamber 122. The plug 124 is retained in the chamber 122 by 
the retaining ring 126, which is preferably formed from alu-
minum and has an opening in the center to permit delivery of 
exhaled breath condensate into the reaction chamber 122 via 
a delivery port 130 in the plug 124. In a preferred embodi-
ment, the delivery port 130 is a re-sealable cover that may be 
punctured with a hypodermic needle. The protective cap 128, 
which is preferably formed from plastic, is temporarily 
attached over the top of the assembly 120 to protect the 
retaining ring 126 and plug 124 from damage or soiling. 
[0092] In use, a sterile reaction chamber assembly 120 is 
retrieved from storage, and an EBC sample is collected using 
one of the disclosed devices 10, 60, 80 (or another equivalent 
device). The protective cap 128 of the reaction chamber 
assembly 120 is removed and a relatively precise volume of 
the EBC sample is then delivered to the reaction chamber 122 
by inserting the respective hypodermic needle 35 in the deliv-
ery port 130 of the plug 124. If provided, the respective luer 
lock fittings may be engaged, effectively locking the device 
10, 60, 80 to the reaction chamber assembly 120. The plunger 
assembly 25 may then be depressed until a sufficient volume 
of EBC is delivered to the assembly 120. A calibration line 
134 may be marked on the reaction chamber 122 to indicate 
the necessary volume, but if the volume has been pre-cali-
brated in the collection device 60, then such a line 134 may 
not be necessary. During assembly, the reaction chamber 122 
may sealed under a vacuum to withdraw a sufficient volume 
of EBC as needed for accurate measurement of endotoxin 
analyte. 
[0093] The chamber 122 contains a prespecified dry mass 
136 of factor C, factor B, proclotting enzyme and chromoge-
nic substrate, together with salts of calcium and magnesium, 
and phosphate salts, or other organic compound, such as 
TRIS aminomethane buffer to maintain a pH of approxi-
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mately 7.4 upon hydration. The amounts and activities of 
these enzymes are precalibrated to allow detection of a clini-
cally relevant range of LPS in the specified volume of EBC. 
The amounts will be calibrated to allow the reaction to pro-
duce a linear optical density reading that ranges from 0 to 1.00 
when measured at 15-30 minutes reaction time at approxi-
mately 37° C., corresponding proportionately to a concentra-
tion of LPS ranging from 0 to approximately 10 EU/mL in 
undiluted EBC. It is preferred that the temperature of the 
reaction be held at least about 34 ° C. It is more preferred that 
the temperature of the reaction be held at least about 37° C. 
[0094] The chromogenic substrate can tolerate tempera-
tures up to about 43 ° C. without loss of activity. As such, the 
reaction chamber may be heated by a controlled exothermic 
reaction up to about 43 ° C. It is preferred that the exothermic 
reaction be controlled in order to produce even incubation at 
34-43° C. for at least 15 minutes, and preferably 25 minutes. 
Accordingly, and as described hereinbelow, steps should be 
taken to control the rate of the exothermic hydration reaction. 
[0095] Such an exothermic reaction may be initiated by 
placing a salt that liberates heat upon hydration within the 
reaction chamber. An example of such a salt includes, but is 
not limited to, sodium thiosulfate pentahydrate. Placing the 
salt within the reaction chamber allows introduction of the 
sampled condensate to initiate the exothermic reaction. It is 
preferred to use a powdered salt, which would facilitate 
immediate and complete hydration within a short heating 
period. For example, the salt may be in a semi-permiable 
matrix or a crystalline form that allows controlled hydration 
to produce a reaction temperature of 34-43 ° C. for at least 15 
minutes. Alternatively, the salt may be disposed in a user-
initiated heating jacket that surrounds the reaction chamber. 
In this embodiment, the reaction chamber may be inserted 
into a double-walled jacket consisting of a flexible polymer. 
The jacket may contain dry salt capable of liberating heat 
upon hydration and an ampule of water (2-5 mL) that can 
easily be ruptured by squeezing with two fingers. The action 
of rupturing the ampule of water initiates hydration of the salt, 
causing an exothermic reaction, thus heating the reaction 
chamber to about 43° C. for approximately 15-30 minutes, at 
which point, the color intensity and corresponding endotoxin 
activity can be quantified as further described herein below. 
[0096] Preliminary data suggest that concentrations ofLPS 
exceeding approximately 0.20 EU/mL (a calibrated linear 
optical density reading of approximately 0.20) will corre-
spond to the clinical test positive threshold, indicating the 
presence of Gram negative bacterial infection in the lungs. In 
the preferred embodiment, the chromogenic substrate may be 
a peptide conjugated to a dye such as para aminoanilde that is 
cleaved by the clotting enzyme to liberate a yellow color to 
the reaction solution with peak absorbance at about 405 nm. 
It should be readily understood that other chromogenic sub-
strates could be substituted, and other dye markers could be 
conjugated to the substrate which can be detected at different 
isobestic points. Additionally, the marker molecule may be a 
compound that contains the property of excitation fluores-
cence, whereby the molecule liberates light within a narrow 
wavelength interval in response to stimulation by an incident 
beam of monochromatic light. One of ordinary skill in the art 
will understand that various chromogenic and fluorogenic 
substrates may be used as markers for detecting the presence 
of the LPS. 
[0097] Alternatively, a reaction chamber assembly may be 
designed to capture LPS using antibodies matrix-bound on 
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the sides of the well. FIG. 9 is a perspective view of a first 
alternative reaction chamber assembly 140. In this alternative 
embodiment, the assembly 140 would function as a vertical 
microtiter well employing enzyme-linked immunoassay 
technology and would have the advantage of allowing detec-
tion of species-specific LPS molecules 154. The assembly 
140, which may function as a cuvette, may include a chamber 
142, a plug 144 and a retaining ring or other structure 146. 
Windows 143 are formed in at least a portion of the walls of 
the chamber 142 for a purpose made evident hereinbelow. 
Like the ring 126 of the previous device 120, the ring 146 
includes an opening that exposes an injection target area 150 
in the center of the plug 144. 
[0098] FIGS. lOA-lOD are partially schematic, fragmen-
tary side cross-sectional views of the first alternative reaction 
chamber assembly 140 of FIG. 9. The Fe portion of each 
antibody 152 is conjugated or bound to the windows 143 of 
the assembly 140 using conventional techniques. The Fab 
portion of each antibody 152 is thus oriented toward the 
center of the assembly 140 to better capture the 0-polysac-
charide portion of the LPS 154. After introduction of the EBC 
sample, the chamber 142 may then be washed with an albu-
min-containing buffer (not shown) to remove nonspecific 
materials. Then, a separate ampule, containing a prespecified 
amount of chromogenic substrates 156, such as those 
described previously, is reconstituted by adding LPS-free 
water (not shown), and the chromogenic reagent sample is 
withdrawn by syringe and injected into the reaction chamber 
142, as shown in FIG. lOC. The chromogenic substrates 156 
react with the LPS 154, thereby liberating a dye 158. After 
approximately 15-30 minutes, optical density may be read by 
one of several methods. One chromogenic substrate 156 suit-
able for use in the preferred embodiments of the present 
invention incorporates para nitroanilide, which when freed 
can be detected at about 405-410 nm. 
[0099] It will be apparent to those of ordinary skill in the art 
that rather than an antibody with specific immunogenicity 
toward 0-antigen, other molecules with specific and high 
affinity for any portion of LPS may be bound to the walls of 
the reaction chamber for capture of LPS. These molecules 
include, but are not limited to, HA-IA and ES, lipopolysac-
charide binding protein ("LPB"), bacteriocidal/permeability 
increasing protein ("BPI"); limulus anti-lipopolysaccharide 
factor ("LALF") or the polymyxin antibiotics. 
[0100] In order to quantify LPS concentration, a number of 
embodiments may be utilized. In one embodiment, a semi-
quantitative determination may be made using a visual com-
parison to a color strip. The color strip may resemble a stan-
dard ruler having patches of one color displayed left to right 
in incrementally increasing degrees of shade intensity, with 
the lightest shade being located furthest left and the darkest 
shade being located furthest right. Each shade patch is asso-
ciated with a specific range of endotoxin unit (EU) reactivity 
with increasing degrees of shade intensity signifying increas-
ing EU reactivity. An observer may hold the clear reaction 
chamber assembly 120, 140 in ambient light next to the plas-
tic or paper color strip for comparing the shade of the contents 
of the reaction chamber assembly 120, 140 with the color 
strip patches. The observer may then select the color patch 
that best matches the color shade intensity observed in the 
reaction chamber. A positive reaction would be indicated by a 
specific color shade threshold, corresponding to approxi-
mately 0.20 EU/mL or as determined from additional experi-
ments. 
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[0101] More precise quantification may be obtained with a 
small, specially designed single beam light spectrophotom-
eter that is configured to accept the reaction chamber after 
incubation as described above. The spectrophotometer may 
contain a heating coil that is activated upon insertion of the 
reaction chamber to warm the sample to 37° F. The spectro-
photometer may alternatively display or print the measure 
optical density after 25 minutes of incubation. 
[0102] FIG. 11 is a perspective view of a test kit 200 incor-
porating a second alternative reaction chamber device, which 
would allow EBC to be delivered to a single-use cartridge that 
could be read visually without the use of a spectrophotometer. 
The test kit 200 has two modules 203, 223, including a test 
module 203 and a positive control module 223, arranged in a 
housing 202. FIG. 12 is a side cross-sectional view of the test 
module 203 of FIG. 11, taken along line 12-12. The test 
module 203 includes a port 204. Port 204 preferably has a 
volume of approximately 100 microliters and contains dry 
mass 136 of factor C, factor B, proclotting enzyme and chro-
mogenic substrate, together with EDTA, salts of calcium and 
magnesium, and phosphate salts, or other organic compound, 
which allows the dry mass to maintain a pH of approximately 
7.4 upon hydration and to form an aqueous reagent. 
[0103] FIG. 11 further shows a reaction chamber 208, a test 
matrix 212, a pair of microtubules 214, 216, a pairofone-way 
valves 218, 220 and an outlet 222. Reaction chamber 208 
preferably has a volume of at least about 250 microliters. The 
port 204 and reaction chamber 208 are connected by the first 
microtubule 214, while the reaction chamber 208 is con-
nected to the outlet 222 by the second microtubule 216. One 
of ordinary skill in the art will understand that microtubule 
214 may include one or more microtubules. Valves 218, 220 
are disposed in the first and second microtubules 214, 216, 
respectively, so as to facilitate one-way fluid communication 
from the port 204 through the reaction chamber 208 to the 
outlet 222. If microtubule 214 includes a plurality of micro-
tubules, more than one valve 218, 220 may be necessary to 
accommodate the plurality of microtubules. The top of the 
cartridge has a preprinted color strip 221 with a series of 
successively darker color patches disposed thereon and 
arranged such that each successively darker color patch cor-
responds to an incrementally greater interval of endotoxin 
activity. 
[0104] The chamber 208 is covered with a clear material 
210 to allow viewing of the matrix 212 for color change 
indicating the presence of LPS. The matrix 212, which is 
arranged in the chamber 208, is a surface formed from an 
insoluble polymer or other material that will accept and be 
stained by the chromogenic substrate. Suitable materials 
include, but are not limited to, polymers derived from cellu-
lose, agarose, methacrylate, polystyrene, polyphenyl, 
polynaphthyl, polybenzyl, nylon, silk or other fabric and the 
like. The matrix 212 is absorbent but tightly woven such that 
it permits fluid to remain suspended in the chamber 208 until 
the fluid moves by gravity and capillary action throughmicro-
tubule 216. As an advantage, the matrix 212 may intrinsically 
bind LPS itself or may covalently or otherwise bind one of the 
LPS-binding molecules, such as HA-IA and E5, LPB, BPI, 
LALF or the polymyxin antibiotics. The matrix 212, there-
fore, develops a color intensity in proportion to the concen-
tration of endotoxin in the unknown sample. Visual compari-
son to the pre-printed color-strip 221 allows a semi-
quantitative determination of endotoxin concentration, as 
described above. 
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[0105] The interior of the test kit 200 may also contain 
sodium thiosulfate pentahydrate and a sealed ampule of water 
that ruptures upon squeezing of the test kit 200. The action of 
rupturing the ampule of water will initiate hydration of the 
sodium thiosulfate, causing an exothermic reaction, thus 
heating the entire test kit 200 to about 43° C. for approxi-
mately 25 minutes. Although the materials for the exothermic 
reaction are disposed within the test kit 200, they are sepa-
rated from all areas of the test kit 200 in which the sample is 
introduced and in which any LPS-related chemical reactions 
occur. 
[0106] In operation, the reaction is initiated by injecting 
condensate collected with device 10, 60, 80 into the chamber 
204 that contains the dry mass 136 described previously. It is 
preferred that at least about 0.35 mL of condensate be injected 
into the reaction chamber 204. The action of injecting the 
condensate causes a mixing action of the condensate and dry 
mass 136 in the reaction chamber 204 and the microtubule 
214, thereby initiating the LAL reaction. The pressure differ-
ential induced by injection, coupled with the force of capil-
lary action causes the reaction mixture to flow down micro-
tubule 214 into the reaction chamber 208, where it remains 
while the chromogenic reaction continues at a temperature of 
34-43° C. Since endotoxin will be bound to the matrix 212, 
the colored molecule that is hydrolyzed from the chromoge-
nic substrate will stain the matrix 212 in a color hue intensity 
that is proportional to the activity of endotoxin in the conden-
sate, the color change can be visually compared with the color 
strip 221 for quantitation. 
[0107] FIG. 13 is a side cross-sectional view of the positive 
control module 223 of FIG. 11, taken along line 13-13. The 
positive control module 223 includes a port 224; a reaction 
chamber 228; a test matrix 232; a quantity of dry LPS com-
bined with dry mass 136, represented herein as 244; a pair of 
microtubules 234, 236; a pair of one-way valves 238, 240 and 
an outlet 242. The port 224 and reaction chamber 228 are 
connected by the first microtubule 234, and the reaction 
chamber 228 is connected to the outlet 242 by the second 
microtubule 236. The valves 238, 240 are disposed in the first 
and second microtubules 234, 236, respectively, so as to per-
mit one-way fluid communication from the port 224 through 
the reaction chamber 228 to the outlet 242. As illustrated, the 
LPS 244 is disposed in the port 224, but it will be apparent that 
the LPS 244 may alternatively or additionally be disposed in 
the first microtubule 234 or on the test matrix 232. 
[0108] The second alternative reaction chamber device 
may also be used as follows. An EBC sample is injected from 
one of the previously-described breath condensate collection 
devices 10, 60, 80 into the test module port 204, from where 
it may be directed via the first test module microtubule 214 to 
the test module reaction chamber 208. In a preferred embodi-
ment, the volume of the EBC sample is about 0.35 mL. The 
volume of the sample is preferably calibrated such that the 
well 208 containing the matrix 212 fills to capacity, thus 
covering the matrix 212 with liquid and initiating LPS bind-
ing to the matrix 212. Excess EBC may flow out through the 
second test module microtubule 216. The one-way valve 218 
prevents entry of LPS from ambient air. Absorbent material 
may be placed in 216 to prevent any external fluid leak. 
[0109] After a relatively precise predetermined period of 
time, which may be about 60 seconds, the test module 203 and 
the positive control module 223 may each be washed with a 
quantity of sterile (endotoxin-free) water. In a preferred 
embodiment, the volume of sterile water that is injected into 
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each module 203, 223 is about 0.25 mL. The water passes 
through the respective reaction chambers 208, 228 and is 
allowed to drain through the respective outlets 222, 242 via 
the respective second microtubule 216, 236. 
[0110] Next, LPS-free water is added to an ampule, such as 
the reaction chamber device 120 of FIGS. 7 and 8, containing 
a dry mass 136 of factor C, factor B, proclotting enzyme and 
chromogenic substrate, together with EDTA, salts of calcium 
and magnesium, and phosphate salts, or other organic com-
pound to maintain a pH of approximately 7.4 upon hydration 
to form an aqueous reagent. Once the reagent is reconstituted, 
it may be withdrawn using a syringe such as that commonly 
used to deliver insulin or to provide tuberculosis testing anti-
gen (often referred to as a "TB syringe") (not shown) and 
injected into both the test module port 204 and the positive 
control module port 224. The test kit 200 may then be left to 
develop for a prespecified time interval, e.g., 10 minutes at 
23 ° C., and then visually inspected for color or pattern change 
in the test well 208. The positive control module 223 is 
included to ensure activity of the chromogenic enzyme sys-
tem. 
[0111] In a still further alternative, the proportion ofLPS in 
EBC could be measured by allowing gel formation of the 
clotting cascade within a narrow tube, as described in Nee-
man et al., U.S. Pat. No. 4,370,413, (the '413 patent), the 
entirety of which is incorporated herein by reference. FIG. 14 
is a partial side cross-sectional view of a breath condensate 
collection device 260 in accordance with a fourth preferred 
embodiment of the present invention. This device 260 is 
similar to that of FIG. 4, in that it includes a syringe 262 
having double walls 22, 32, a central chamber 24, a plunger 
assembly 65 with a piston 26, a rubber gasket 28 and a handle 
30, a breath input assembly (not shown), an outlet 68, a 
threaded nozzle 61, and a removable plastic covering 69. 
Each of these components is generally similar to those of the 
device 60 of FIG. 4, except that the syringe 262 further 
includes a manometer 265 extending from the side of the 
syringe in fluid communication with the outlet 68. In addi-
tion, although each device 60, 260 includes a needle 35, 275, 
the needle 27 5 of this fourth embodiment serves as the narrow 
tube in which EBC is contacted with the LAL assay reagent. 
Accordingly, the needle 275 is plugged with a dry, insoluble 
and inert fiber matrix 270, as shown in FIG. 15, which is 
preloaded with the LAL assay reagent for gelation if LPS is 
present in the EBC. 
[0112] A reaction may be initiated by depressing the 
plunger assembly 65 until the plug 270 is wetted with EBC. 
The amount of gelation in the outflow needle 275 will be 
proportional to the amount ofLPS in the EBC. After a speci-
fied period of time, the plunger assembly 65 may be forcibly 
depressed again, and the extrusion pressure measured within 
the central chamber 24 using the manometer 265. The extru-
sion pressure is proportional to the LPS concentration in the 
EBC. 
[0113] In all of the preceding embodiments, it should be 
recognized that the specificity of the reaction can be enhanced 
by inclusion of chemicals or methods to prevent reaction with 
beta glucans (factor G), including heating the sample to 75° 
C., adding alkylglucosides, or molecules with beta 1,4 glu-
cosidic linkages. 
[0114] Once a Gram negative bacterial infection is diag-
nosed, antibiotic therapy may begin. Those skilled in the art 
will understand that the method of the present invention may 
be utilized to monitor the effectiveness of antibiotic therapy. 
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It can be predicted by those skilled in the art, that effective 
antibiotic therapy may cause an initial increase in LPS con-
centration in expired breath condensate, owing to bacterial 
demise with cell membrane rupture and increased release of 
free LPS into alveolar epithelial fluid. This concentration 
increase would be expected in the first 24 to 72 hours after 
antibiotic administration. It could further be predicted that 
effective antibiotic therapy would eventually cause a decrease 
in the concentration ofLPS in expired breath condensate over 
the subsequent 3-10 days after antibiotic administration. 
Accordingly, it can be surmised that serial LPS measurements 
may be used to monitor treatment efficacy. A failure to exhibit 
an initial increase in expired LPS content or a failure to 
exhibit a decline in expired LPS content in the subsequent 
days could signal resistance of the Gram negative bacteria to 
treatment. 
[0115] The present invention is advantageous because it 
provides a method and device for diagnosing a Gram negative 
bacterial infection in a relatively easy, painless and quick 
manner. The present application is directed to diagnosing 
Gram negative bacterial pneumonia by measuring the con-
centration ofLPS in exhaled breath condensate. However, the 
present invention may also be utilized to diagnose any intra-
pulmonary Gram negative bacterial infection, including, but 
not limited to, septicemia. One of ordinary skill in the art will 
understand that Gram negative bacterial infections may be 
treated with the same antibiotic treatment and thus diagnoses 
of any Gram negative bacterial infection is beneficial for a 
subject suffering from such infection. Further, the present 
invention may also be utilized to identify a specific strain of 
Gram negative bacteria causing infection in a situation in 
which this information may be beneficial. 
[0116] Another embodiment of the breath condensate col-
lection device in accordance with the present invention is 
shown in FIG. 16. FIG. 16 is an overall cross-sectional view 
of breath condensation collection device 300. The breath 
condensation collection device 300 comprises a breath input 
assembly or mouthpiece 310 connected to a central conden-
sation chamber 320, having an interior and first and second 
opposing ends, into which the patient breathes and conden-
sate is collected inside the central chamber 320. The breath 
condensate collection device 300 further comprises a plunger 
assembly 330 comprising, at opposing ends, a handle and a 
plunger disk 350 that functions as a piston. The plunger disk 
350 is slidably disposed in the interior of the central chamber 
and the handle extends from the first end of the central cham-
ber so as to permit the piston to be moved within the central 
chamber. The plunger assembly 330 is depressed to extrude 
the collected liquid through an exit assembly disposed at an 
end of the central chamber 320, the exit assembly comprised 
of a nose section 340 narrowing from the central chamber 320 
and terminating with an open nose hole 345. FIG. 16 shows a 
plunger disk 350 comprised of a material such as rubber 
connected to the plunger assembly 330 that functions as a 
piston to collect the condensate and gather it at the nose end. 
A stopper 360 has an embedded hypodermic needle 380. The 
stopper 360 is connected to the plunger disk 350 by a plurality 
of support pins 370 and is configured for sealing engagement 
within the nose section 340 of the exit assembly when the 
plunger assembly 330 is depressed, whereby the collected 
breath condensate may be expelled from the central chamber 
320 via the hypodermic needle 380. When the plunger assem-
bly 330 is depressed, the stopper 360 seats in the nose 340 and 
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leaves a certain distance that is determined by how far the 
stopper is supported off the disk with the support pins 370. 
[0117] FIG. 17 is an enlarged cross-sectional view of the 
stopper 360 in the nose 340 of the breath condensate collec-
tion device 300 of FIG. 16. FIG. 17 shows a close-up of the 
stopper 360 in the nose 340, assuming the plunger 330 is 
almost completely depressed. At this point, the stopper 360 
has made a seal with the nose 340. The pins 370 suspend the 
stopper 360 to a distance that corresponds to a desired vol-
ume, such as 100 or 200 µL. Any volume of condensate that 
exceeds this amount exits the nose hole 345 before the stopper 
360 seats. After the stopper 360 seats, however, the trapped 
condensate takes the path ofleast resistance, which is through 
a hypodermic needle 380 that is imbedded in the center of the 
stopper 360. The top of the hypodermic needle 380 is open to 
the condensation chamber 320. The needle tip 385 can be 
punctured into an analyzer chamber and the sample extruded 
in sterile fashion. FIG. 17 illustrates that there is a plurality of 
predrilled holes 355 in the plunger disk 350. The tapered end 
375 of the pins 370 drive into predrilled holes 355 in the 
plunger disk 350 when the stopper 360 seats in nose 340. The 
pin370 is placed at a band390 (shown in FIG.18) to calibrate 
volume. Thus, the stopper 360 is seated in the nose 340 
creating a seal with continued pressure. The pins 370 drive 
into the plunger disk 350 and condensate ejects out. 
[0118] FIG.18 is an enlarged side view of a support pin 370 
as showninFIG.16. FIG.18 shows a close-up ofa support pin 
370 which has a collar or flare 378 to stabilize the pin 370 in 
the stopper and to prevent the pin 370 from driving into the 
rubber on that side. The top of each pin 370 fits into a pre-
drilled hole that allows for a snug but non-binding fit of the 
top ofthepin370 in the disk350 atthe end of the plunger 330. 
As shown inFIG.17, the top of each of three pins 370 fits into 
one of three predrilled holes 355. The resistance of the pins 
370 to travel through the disk 350 is sufficient to maintain a 
seal between the stopper 360 and the nose 340. FIG. 18 
illustrates a tapered end 375 of the pin 370. The bands 390 
shown in FIG. 18 correspond to a volume. The collar 378 
stabilizes the post in the rubber. 
[0119] FIG. 19 is a top view of a stopper 360 as shown in 
FIG. 16. FIG.19 shows the top of the stopper 360 to illustrate 
the relation of where the pins 370 reside relative to the open-
ing of the central hypodermic needle 380. The hypodermic 
needle 380 has an opening for condensate. The support pins 
370 are also illustrated in FIG. 19. 
[0120] There are advantageous aspects of this embodiment 
of the present invention. The present invention does not 
require excessively precise milling to produce a tip that seals 
precisely and allows egress of condensate into an imbedded 
cannaliculi. An advantage of this embodiment is that the 
stopper is not fixed to the disk. Furthermore, until the present 
invention, there has not been a good method to ensure direc-
tion of flow through a self-contained needle which is desir-
able because the more steps needed to attach a needle 
increases the chance of contaminating a sample. Thus, the 
embodiment of the device of the present invention shown in 
FIG. 16 provides a method of operation such that a stopper 
permits a calibrated volume of condensate to be ejected in a 
single operation. 
EXAMPLES 
Example 1 
[0121] LPS was detected in exhaled breath condensate 
samples from subjects that were awake, cooperative and able 
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to breathe spontaneously in order to diagnose whether such 
subjects had Gram negative bacterial pneumonia according to 
the following procedure. 
[0122] The subjects for the procedure were selected 
according to the following procedure. Subjects (N=S per 
group) were recruited based upon three criteria: 1) diagnosis 
of pneumonia, 2) healthy patients who actively smoked more 
than 10 cigarettes per day and 3) healthy nonsmokers. To 
obtain subjects diagnosed with pneumonia, subjects diag-
nosed on standard clinical grounds, including cough produc-
tive of colored sputum, measured fever> 101 ° F., a leukocy-
tosis, evidenced by a peripheral total white blood count of 
> 12,000 cells per cubic microliter, and the presence of an 
infiltrate on chest radiograph were selected. Exclusion crite-
ria for subjects included any use of antimicrobial medica-
tions, acute illness or anatomical abnormality that precluded 
breath collection and/or suspected pulmonary tuberculosis. 
[0123] The breath condensing device utilized for collected 
exhaled breath samples is described as follows. The device 
consisted of a one-meter long polyvinyl tube (15 mm ID) 
attached to a modified glass flask, which was approximately 
50 cm in height. The glass flask had a specially designed, 
removable glass stopper at the top but was otherwise similar 
in appearance to a standard laboratory volumetric (Florence) 
flask. The glass stopper had two ports, one for entry of a glass 
tube that projected upward and was bent at a 90° angle and 
another to allow dried, exhaled air to exit into ambient air. 
One end of the glass tube was connected to a polyvinyl tube 
that fit snugly over the glass tube. The other end of the glass 
tube projected into the interior of the glass bulb of the flask by 
approximately 25 cm. The entire glass flask was submerged in 
a cooling slurry of frozen carbon dioxide in ethanol. 
[0124] Exhaled breath condensate was collected according 
to the following procedure. A subject was allowed to hold the 
polyvinyl tube and breath into a duckbill-shaped mouthpiece 
that was attached to the opposite end of the polyvinyl tube. 
The subject's breath passed through the polyvinyl tube into 
the condenser chamber of the flask, where the cooled inner 
side of the flask would condense and freeze the expired water 
vapor and aerosolized droplets in the subject's breath. Sub-
jects were asked to deliver approximately 30 deep exhala-
tions, which yielded approximately 1-3 mL of sample. 
[0125] Prior to collection of breath samples from subjects, 
multiple steps were take to reduce sample contamination with 
extraneous endotoxin or beta glucan molecules. All compo-
nents were sterilized by autoclaving at 220° C. for a minimum 
of 4 hours between uses and by using a commercially avail-
able washing solution designed to remove endotoxin. The 
polyvinyl tube was wrapped in sterile foil prior to autoclav-
ing. The sterile foil was left in place during sample collection 
but was removed prior to removing the polyvinyl tube. The 
technician used sterile gloves to handle all components. How-
ever, the terminal 6 cm of the polyvinyl tube was able to be 
grasped by the subject, who did not wear sterile gloves. After 
the condensate was allowed to melt, it was aspirated from the 
condenser chamber with pyrogen-free pipette tips and trans-
ferred to pyrogen-free cryotubes under a laminar hood. To 
examine for background endotoxin, a "mock" standard of the 
glassware and tubing was conducted according to the follow-
ing procedure. Two milliliters of endotoxin-free water 
(Sigma Chemical, St. Louis, Mo.) was instilled into the 
washed, autoclaved condenser chamber, agitated and then 
aspirated and stored in the same manner as the condensate 
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samples. Condensate samples and the water run for a mock 
standard were stored at -57° C. until assay. 
[0126] The presence of endotoxin was detected according 
to the following procedure. An assay was performed on undi-
luted, thawed condensate using a chromogenic limulus assay 
according to manufacturer's specifications (Pyrochrome 
Assay, Associates of Cape Cod, Falmouth, Mass., USA). 
Reactions were carried out on 96-well microtitre plates (Py-
rochrome microtitre plates, Associates of Cape Cod) at 3 7° C. 
for 30 min, and the color change read with a microtitre plate 
spectrophotometer at 405 nm. All samples were run during 
one batch. The standard curve was performed using the assay 
endotoxin standard and was linear with R=0.997. 
[0127] FIG. 20 is a scatter plot graph illustrating the mea-
sured endotoxin concentrations for patients in each of three 
study groups. The mean (±SD) endotoxin concentration in 
normals, smokers, and patients with pneumonia was 0.096±0. 
050, 0.091±0.040, and 0.234±0.130 EU/mL, respectively. 
The plot suggests that 0.20 EU/mL may be a useful cutoff 
point to distinguish subjects with Gram negative pneumonia 
from subjects without Gram negative pneumonia. 
[0128] Two subjects with pneumonia and test values below 
0.20 EU/mL are labeled "A" and "B". Traditional clinical 
tests confirmed that these subjects did not have Gram negative 
bacterial pneumonia. Patient A had blood cultures that were 
positive for streptococcus pneumonia, which was clinically 
presumed to be the bacterial cause of the patient's pneumo-
nia; patient B had clinically suspected influenza! (viral) pneu-
monia with negative blood cultures and no other specimens 
submitted for analysis. 
[0129] Two of the water samples from the mock standard 
had values of 0.10 and 0.14 EU/mL (mean 0.12 EU/mL). 
Accordingly, 0.12 EU/mL was considered the background 
"noise" of the system, and this value was subtracted from the 
cutoff value of 0.20 EU/mL determined in uncorrected 
samples. Using this analysis, a sample of expired breath con-
densate containing a value above 0.08 EU/mL would be con-
sidered an abnormal test result. It should be recognized that 
this background correction value may differ if a different 
condenser apparatus is used in another laboratory. 
Example 2 
[0130] LPS was detected in exhaled breath condensate 
samples from subjects that were breathing with the assistance 
of a ventilator in order to diagnose whether such subjects had 
Gram negative bacterial pneumonia according to the follow-
ing procedure. 
[0131] Six subjects participated in the study. Four of the 
ventilated subjects presented clinical evidence of pneumonia 
and were being treated with antibiotic therapy, and two of the 
ventilated subjects presented no clinical evidence of pneumo-
nia and were used as controls. 
[0132] Breath condensate samples were obtained accord-
ing to the following procedure. The analyte was obtained 
from the exhaled breath condensate that accumulated in out-
flow tubing attached to the endotracheal tube of the ventila-
tion system. Analyte appeared clear and non-turbid upon 
visual inspection. 
[0133] The presence of endotoxin was detected according 
to the following procedure. An assay was performed on undi-
luted and diluted condensate using a chromogenic limulus 
assay according to manufacturer's specifications (Pyro-
chrome Assay, Associates of Cape Cod, Falmouth, Mass., 
USA). The dilutions included 1:10, 1:100 and 1: 1000 dilu-
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tions in endotoxin-free water. Reactions were carried out on 
96-well microtitre plates (Pyrochrome microtitre plates, 
Associates of Cape Cod) at 37° C. for 30 minutes, and the 
color change read with a microtitre plate spectrophotometer 
at 405 nm. All samples were run during one batch. The upper 
limit of detection of the assay was 0.25 EU/mL. 
[0134] The results of the assay are as follows. All six 
samples were above limits of detection in the undiluted 
samples (i.e., greater than 0.25 EU/mL ). The mean endotoxin 
concentration in all the 1: 10 dilution samples of subjects with 
pneumonia was above the limit of linear detection, but the 
mean endotoxin concentration from the two ventilated 
patients without pneumonia in the 1: 10 dilutions was <0.05 
EU/mL. These data suggest that the presence of more than 
0.25 EU/mL in samples of condensate in the outflow tubing of 
a ventilator circuit that appear clear and non-turbid upon 
visual inspection would predict the presence of a bronchoal-
veolar lavage sample that would be positive for gram negative 
pneumonia. 
Example 3 
[0135] LPS was detected in exhaled breath condensate 
according to the following procedure. A commercially avail-
able I-liter volume glass flask was prepared for collecting 
breath condensate samples according to the following proce-
dure. The glass was heated to 400° C. for 3 hours to render its 
surfaces LPS-free. A sterilized, flexible polyvinyl tube, 11 
mm in internal diameter, was arranged in fluid communica-
tion to a side-arm of the flask such that when a patient 
breathed into the tube, the patient's breath passed through the 
glass flask and out through an exit port. The flask was partially 
submerged in a dry ice and ethanol slurry mixture as a coolant 
to facilitate capture of exhaled breath condensate in the flask. 
The tube and flask were arranged in a fashion to keep the 
condensing flask above the level of the patient to prevent any 
capture of aerosolized saliva. 
[0136] Exhaled breath was collected according to the fol-
lowing procedure. Eight subjects of varying health status 
breathed into the tube connected to the flask. Each subject 
breathed 100 deep exhalations into the flask, using a hand 
counter to keep track of breaths. This method provided a 
mean volume of condensate equal to 11 ±4 mL. 
[0137] A chromogenic commercial LAL assay (Cape Cod, 
Mass.) was used to detect LPS in the exhaled breath conden-
sate according to the following procedure. From each sub-
ject's condensate sample, duplicate 50 µL aliquots were 
transferred into two wells of a standard 96-well ELISA plate. 
The reagents required for the chromogenic LAL assay were 
added and the samples were incubated for 30 minutes at 37° 
C. The optical density was read at 405 nm in a commercially 
available plate well reader. Concentrations were determined 
by comparison to a standard curve using known amounts of 
LPS obtained from a FDA-certified source. 
[0138] Results were obtained as follows. Four normal vol-
unteers were all found to have concentrations of LPS below 
100 pg/mL, whereas two otherwise healthy smokers were 
found to have concentrations below 200 pg/mL. Two smokers 
with clinical pneumonia were found to have EBC LPS con-
centrations above 800 pg/mL. From this experiment, it was 
concluded that LPS content of EBC samples can vary based 
upon the health of the lung in the subjects providing the 
samples. These data also suggest that EBC can be sampled 
without contamination from oral flora in healthy subjects. 
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[0139] Based on the foregoing information, it is readily 
understood by those persons skilled in the art that the present 
invention is susceptible of broad utility and application. Many 
embodiments and adaptations of the present invention other 
than those specifically described herein, as well as many 
variations, modifications, and equivalent arrangements, will 
be apparent from or reasonably suggested by the present 
invention and the foregoing descriptions thereof, without 
departing from the substance or scope of the present inven-
tion. Accordingly, while the present invention has been 
described herein in detail in relation to its preferred embodi-
ment, it is to be understood that this disclosure is only illus-
trative and exemplary of the present invention and is made 
merely for the purpose of providing a full and enabling dis-
closure of the invention. The foregoing disclosure is not 
intended to be construed to limit the present invention or 
otherwise exclude any such other embodiments, adaptations, 
variations, modifications or equivalent arrangements; the 
present invention being limited only by the claims appended 
hereto and the equivalents thereof. Although specific terms 
are employed herein, they are used in a generic and descrip-
tive sense only and not for the purpose oflimitation. 
What is claimed is: 
1. A device for collecting exhaled breath condensate from 
a subject, comprising: 
a central chamber having an interior and first and second 
opposing ends; 
a breath input assembly, disposed near the first end of the 
central chamber, in fluid communication with the inte-
rior of the central chamber; 
an exit assembly, disposed at the second end of the central 
chamber, in fluid communication with the interior of the 
central chamber, wherein the exit assembly comprises a 
nose section narrowing from the central chamber and 
terminating with an open nose hole; 
a plunger assembly comprising a piston having a handle 
and a plunger disk at opposing ends, wherein the plunger 
disk of the piston is slidably disposed in the interior of 
the central chamber and wherein the handle extends 
from the first end of the central chamber so as to permit 
the piston to be moved within the central chamber; and 
a stopper having an embedded hypodermic needle, 
wherein the stopper is connected to the plunger disk by 
a plurality of support pins and is configured for sealing 
engagement within the nose section of the exit assembly 
when the plunger assembly is depressed, whereby the 
collected breath condensate may be expelled from the 
central chamber via the hypodermic needle. 
2. The device according to claim 1, wherein a support pin 
comprises at least one marking. 
3. The device according to claim 2, wherein the at least one 
marking is a band. 
4. The device according to claim 3, wherein the band indi-
cates a volume level. 
5. The device according to claim 1, wherein the support 
pins suspend the stopper to a distance that corresponds to a 
desired volume. 
6. The device according to claim 1, wherein the plunger 
disk comprises a plurality of predrilled holes. 
7. The device according to claim 1, wherein a pin com-
prises at least one tapered end. 
8. The device according to claim 7, wherein the tapered end 
of the pin is driven into a predrilled hole in the plunger disk 
when the stopper sits in the nose. 
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9. The device according to claim 1, wherein the stopper is 
comprised of rubber or other penetrable material. 
10. The device according to claim 1, wherein the plunger 
disk is comprised of rubber or other penetrable material. 
11. The device according to claim 1, wherein the pin is 
placed at a band to calibrate a volume ofliquid condensate. 
12. The device according to claim 1, wherein the pin has a 
collar. 
13. The device according to claim 1, wherein the collar 
prevents the pin from driving into the rubber. 
14. The device according to claim 1, wherein the collar 
stabilizes the pin in the stopper. 
15. The device according to claim 1, wherein a top of the 
pin fits into a predrilled hole in the plunger disk. 
16. The device according to claim 1, wherein a seal is 
maintained between the stopper and nose when support pins 
travel through the disk. 
17. The device according to claim 1, wherein the support 
pin comprises a band. 
18. The device according to claim 1, wherein the stopper is 
not fixed to the plunger disk. 
19. The device according to claim 1, wherein the stopper 
permits a calibrated volume of condensate to be ejected. 
20. A method for diagnosing and monitoring intrapulmo-
nary Gram negative bacterial infection in an air-breathing 
vertebrate subject, comprising: 
providing a collection device comprising 
a central chamber having an interior and first and second 
opposing ends; 
a breath input assembly, disposed near said first end of 
the central chamber, in fluid communication with the 
interior of the central chamber; 
an exit assembly, disposed at said second end of the 
central chamber, in fluid communication with the 
interior of the central chamber, wherein said exit 
assembly comprises a nose section narrowing from 
the central chamber and terminating with an open 
nose hole; 
a plunger assembly comprising a piston having a handle 
and a plunger disk at opposing ends, wherein the 
plunger disk of the piston is slidably disposed in the 
interiorof the central chamber and wherein the handle 
extends from the first end of the central chamber so as 
to permit the piston to be moved within the central 
chamber; and 
a stopper having an embedded hypodermic needle, 
wherein the stopper is connected to the plunger disk 
by a plurality of support pins and is configured for 
sealing engagement within the nose section of the exit 
assembly when the plunger assembly is depressed, 
whereby the collected breath condensate may be 
expelled from the central chamber via the hypodermic 
needle; 
collecting exhaled breath condensate from an air-breathing 
vertebrate subject; 
measuring the concentration of lipopolysaccharide in the 
collected exhaled breath condensate; and 
determining whether the subject has an intrapulmonary 
Gram negative bacterial infection based on the measured 
concentration of lipopolysaccharide in the exhaled 
breath condensate. 
* * * * * 
